Estados Unidos - inglês - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - metoprolol tartrate (unii: w5s57y3a5l) (metoprolol - unii:geb06nhm23) - metoprolol tartrate 25 mg - metoprolol tartrate tablets, usp are indicated for the treatment of hypertension. they may be used alone or in combination with other antihypertensive agents. metoprolol tartrate tablets, usp are indicated in the long-term treatment of angina pectoris. metoprolol tartrate tablets, usp are indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality when used alone or in conjunction with intravenous metoprolol. oral metoprolol tartrate tablets, usp therapy can be initiated after intravenous metoprolol therapy or, alternatively, oral treatment can begin within 3 to 10 days of the acute event (see dosage and administration ,  contraindications and warnings ). metoprolol tartrate tablets are contraindicated in sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure (see warnings ). hypersensitivity

Estados Unidos - inglês - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - metoprolol tartrate (unii: w5s57y3a5l) (metoprolol - unii:geb06nhm23) - metoprolol tartrate 25 mg - metoprolol tartrate tablets, usp are indicated for the treatment of hypertension. they may be used alone or in combination with other antihypertensive agents. metoprolol tartrate tablets, usp are indicated in the long-term treatment of angina pectoris. metoprolol tartrate tablets, usp are indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality when used alone or in conjunction with intravenous metoprolol. oral metoprolol tartrate tablets, usp therapy can be initiated after intravenous metoprolol therapy or, alternatively, oral treatment can begin within 3 to 10 days of the acute event (see dosage and administration, contraindications, and warnings). metoprolol tartrate tablets are contraindicated in sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure (see warnings ). hypersensitvity to metoprolol and related derivatives, or to any of the excipients; hypersensit

Estados Unidos - inglês - NLM (National Library of Medicine)

acetris health, llc - metoprolol tartrate (unii: w5s57y3a5l) (metoprolol - unii:geb06nhm23) - metoprolol tartrate 25 mg - hypertension metoprolol tartrate tablets, usp are indicated for the treatment of hypertension. they may be used alone or in combination with other antihypertensive agents. angina pectoris metoprolol tartrate tablets, usp are indicated in the long-term treatment of angina pectoris. myocardial infarction metoprolol tartrate tablets, usp are indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality when used alone or in conjunction with intravenous metoprolol. oral metoprolol tartrate tablets, usp therapy can be initiated after intravenous metoprolol therapy or, alternatively, oral treatment can begin within 3 to 10 days of the acute event (see dosage and administration , contraindications , and warnings ). hypertension and angina metoprolol tartrate tablets are contraindicated in sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure (see warnings). hypersensitivity to m

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - captopril 5 mg/ml - oral solution - 5 mg/ml - active: captopril 5 mg/ml excipient: citric acid monohydrate disodium edetate purified water sodium benzoate sodium citrate - dp-captopril is indicated for the treatment of hypertension. in using dp-captopril, consideration should be given to the risk of neutropenia/agranulocytosis (see section 4.4 special warnings and precautions for use). dp-captopril is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of captopril and thiazides are approximately additive.

Estados Unidos - inglês - NLM (National Library of Medicine)

hospira, inc. - metoprolol tartrate (unii: w5s57y3a5l) (metoprolol - unii:geb06nhm23) - metoprolol tartrate 1 mg in 1 ml - metoprolol tartrate injection is indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality when used in conjunction with oral metoprolol tartrate maintenance therapy. treatment with intravenous metoprolol tartrate can be initiated as soon as the patient's clinical condition allows (see dosage and administration,  contraindications , and warnings ). hypersensitivity to metoprolol tartrate and related derivatives, or to any of the excipients; hypersensitivity to other beta-blockers (cross sensitivity between beta-blockers can occur). metoprolol tartrate is contraindicated in patients with a heart rate <45 beats/min; second- and third-degree heart block; significant first-degree heart block (p-r interval ≥0.24 sec); systolic blood pressure <100 mmhg; or moderate-to-severe cardiac failure (see warnings ).

Estados Unidos - inglês - NLM (National Library of Medicine)

gland pharma limited - metoprolol tartrate (unii: w5s57y3a5l) (metoprolol - unii:geb06nhm23) - metoprolol tartrate 5 mg in 5 ml - metoprolol tartrate injection is indicated in the treatment of definite or suspected acute myocardial infarction in hemodynamically stable patients to reduce cardiovascular mortality when used in conjunction with oral metoprolol maintenance therapy. hypersensitivity to metoprolol and related derivatives, or to any of the excipients; hypersensitivity to other beta blockers (cross sensitivity between beta blockers can occur). metoprolol is contraindicated in patients with a heart rate <45 beats/min; second-and third-degree heart block (unless a functioning pacemaker is present); significant first-degree heart block (p-r interval ≥0.24 sec); systolic blood pressure <100 mmhg; or decompensated cardiac failure. risk summary available data from published observational studies have not demonstrated an association of adverse developmental outcomes with maternal use of metoprolol during pregnancy (see data). untreated hypertension and heart failure during pregnancy can lead to adverse outcomes for the mother and the

Estados Unidos - inglês - NLM (National Library of Medicine)

trigen laboratories, llc - metoprolol tartrate (unii: w5s57y3a5l) (metoprolol - unii:geb06nhm23), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - metoprolol tartrate 50 mg - metoprolol tartrate and hydrochlorothiazide tablets are indicated for the management of hypertension this fixed-combination drug is not indicated for initial therapy of hypertension. if the fixed combination represents the dose titrated to the individual patient’s needs, therapy with the fixed combination may be more convenient than with the separate components. metoprolol metoprolol tartrate tablets are contraindicated in sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure (see warnings). hypersensitivity to metoprolol tartrate and related derivatives, or to any of the excipients; hypersensitivity to other beta blockers (cross sensitivity between beta blockers can occur). sick-sinus syndrome. severe peripheral arterial circulatory disorders. hydrochlorothiazide hydrochlorothiazide is contraindicated in patients with anuria or hypersensitivity to this or other sulfonamide-derived drugs (see warnings).

Estados Unidos - inglês - NLM (National Library of Medicine)

american health packaging - metoprolol succinate (unii: th25pd4ccb) (metoprolol - unii:geb06nhm23) - metoprolol tartrate 100 mg - metoprolol succinate extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic

Estados Unidos - inglês - NLM (National Library of Medicine)

sagent pharmaceuticals - metoprolol tartrate (unii: w5s57y3a5l) (metoprolol - unii:geb06nhm23) - metoprolol tartrate 1 mg in 1 ml - metoprolol tartrate injection is indicated in the treatment of definite or suspected acute myocardial infarction in hemodynamically stable patients to reduce cardiovascular mortality when used in conjunction with oral metoprolol maintenance therapy. hypersensitivity to metoprolol and related derivatives, or to any of the excipients; hypersensitivity to other beta blockers (cross sensitivity between beta blockers can occur). metoprolol is contraindicated in patients with a heart rate <45 beats/min; second- and third-degree heart block (unless a functioning pacemaker is present); significant first-degree heart block (p-r interval ≥0.24 sec); systolic blood pressure <100 mmhg; or decompensated cardiac failure. risk summary available data from published observational studies have not demonstrated an association of adverse developmental outcomes with maternal use of metoprolol during pregnancy (see data). untreated hypertension and heart failure during pregnancy can lead to adverse outcomes for the mother and the

Estados Unidos - inglês - NLM (National Library of Medicine)

athenex pharmaceutical division, llc. - metoprolol tartrate (unii: w5s57y3a5l) (metoprolol - unii:geb06nhm23) - metoprolol tartrate 5 mg in 5 ml - metoprolol tartrate injection is indicated in the treatment of definite or suspected acute myocardial infarction in hemodynamically stable patients to reduce cardiovascular mortality when used in conjunction with oral metoprolol maintenance therapy. hypersensitivity to metoprolol and related derivatives, or to any of the excipients; hypersensitivity to other beta blockers (cross sensitivity between beta blockers can occur). metoprolol is contraindicated in patients with a heart rate <45 beats/min; second- and third-degree heart block (unless a functioning pacemaker is present); significant first-degree heart block (p-r interval ≥0.24 sec); systolic blood pressure <100 mmhg; or decompensated cardiac failure. risk summary available data from published observational studies have not demonstrated an association of adverse developmental outcomes with maternal use of metoprolol during pregnancy (see data). untreated hypertension and heart failure during pregnancy can lead to adverse outcomes for the mother and the